

HOFLAND et al.  
Appl. No. 10/591,847  
Atty. Ref.: 620-454  
Amendment After final Rejection  
November 12, 2009

**IN THE CLAIMS:**

Please amend the claims as follows:

1. (Currently Amended) A method of treatment of a tumour cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison in combination with a bis-dioxypiperazine, wherein said subject is further treated with brain radiation therapy.
2. (Original) A method according to claim 1 wherein the topoisomerase-II poison is etoposide.
3. (Previously Presented) A method according to claim 1 wherein the bis-dioxypiperazine is dextrazoxane.
4. (Previously Presented) A method according to claim 1, wherein the tumour is a CNS tumour.

Claim 5. (Canceled)

6. (Currently Amended) A topoisomerase-II poison, a bis-dioxypiperazine and a source of ionising radiation as a combined preparation for simultaneous, separate or sequential of the topoisomerase-II poison and bis-dioxypiperazine and separate or sequential use of the source of ionising radiation whole brain radiation in tumour therapy.

7. (Currently Amended) A topoisomerase-II poison, a bis-dioxypiperazine and ionising radiation whole brain radiation as a combined preparation for separate or

HOFLAND et al.  
Appl. No. 10/591,847  
Atty. Ref.: 620-454  
Amendment After final Rejection  
November 12, 2009

sequential use in tumour therapy.

8. (Original) A combined preparation for use according to claim 7 wherein the topoisomerase-II poison is etoposide.

9. (Previously Presented) A combined preparation for use according to claim 7 wherein the bis-dioxypiperazine is dextrazoxane.

10. (Previously Presented) A combined preparation for use according to claim 7, wherein the tumour is a CNS tumour.